Skip to main content

Table 2 A complete list of the EVRAAS study outcomes

From: The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial

Primary outcome Secondary outcomes
1. Evaluation of repigmentation of vitiligous lesions achieved after the administration of 1% simvastatin-acid sodium salt or 1% atorvastatin calcium salt ointments compared with vehicle ointment after a 12-week study period (change from baseline in repigmentation on BSA and VASI scale). 1. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.0
2. Percentage of patients who achieved particular response rate in each arm assessed as a relative reduction in lesional skin area as follows: none, 0%; poor, 1–25%; moderate, 26–50%; good, 51–75%; excellent, > 75%
3. Percentage of patients who achieved particular response rate in each arm assessed as a relative reduction in BSA scale as follows: none, 0%; poor, 1–25%; moderate, 26–50%; good, 51–75%; excellent, > 75%
4. Percentage of patients who achieved particular response rate in each arm assessed as a relative reduction in VASI scale as follows: none, 0%; poor, 1–25%; moderate, 26–50%; good, 51–75%; excellent, > 75%
5. Comparison of simvastatin and atorvastatin efficacy between study participants
6. The association between disease duration and repigmentation rate in study arms
7. The association between estimated daily ointment use (grams per square centimeter of skin) and repigmentation rate in study arms
  1. BSA body surface area, CTCAE Common Terminology Criteria for Adverse Events, VASI Vitiligo Area Scoring Index